HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•AuntMinnie
Study: Computer Vision Models Best LLMs in Chest CT Breast Abnormality Detection
Computer vision models (CVMs) surpass large language models (LLMs) in accurately labeling incidental breast abnormalities on chest CT scans.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.